SCHEMBL19920764

SCHEMBL19920764

CN(C)C(=O)C1(NC(=O)OCc2ccccc2)CC(F)(F)C1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSB P07858 6/20 0.48
CTSS P25774 6/20 0.48
CTSL P07711 5/20 0.48
SMN1; SMN2 Q16637 3/20 0.43
CYP3A4 P08684 3/20 0.42
TSHR P16473 1/20 0.42
CTSK P43235 5/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
ALDH1A1 P00352 2/20 0.41
LMNA P02545 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
ATM Q13315 1/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19900624 0.85 CTSS (0.50) CTSBCTSSCTSLSMN1; SMN2TSHR
SCHEMBL5520069 0.85 CTSS (0.62) CTSBCTSSCTSLSMN1; SMN2CYP3A4
SCHEMBL19900776 0.85 CTSB (0.50) CTSBCTSSCTSLSMN1; SMN2CYP3A4
SCHEMBL19920827 0.84 CTSB (0.49) CTSBCTSSCTSLSMN1; SMN2TSHR
SCHEMBL29857191 0.83 CTSS (0.48) CTSBCTSSCTSLSMN1; SMN2TSHR
SCHEMBL28715363 0.81 CTSS (0.47) CTSBCTSSCTSLSMN1; SMN2CTSK
SCHEMBL19920812 0.79 LMNA (0.44) CTSBCTSSCTSLSMN1; SMN2CYP3A4
SCHEMBL18398659 0.78 CTSS (0.54) CTSBCTSSCTSLSMN1; SMN2TSHR
SCHEMBL21760478 0.77 CYP3A4 (0.42) CTSBCTSSCTSLSMN1; SMN2CYP3A4
SCHEMBL19920713 0.77 CTSS (0.46) CTSBCTSSCTSLSMN1; SMN2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12161625-B2 Substituted pyrrolizine compounds and uses thereof GILEAD SCIENCES, INC. (US) 2024-12-10 US disclosed
EP-3922634-B1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES INC (US) 2023-10-25 EP disclosed
EP-3922634-B1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES INC (US) 2023-10-25 EP disclosed
US-20230270719-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2023-08-31 US disclosed
US-20230270719-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2023-08-31 US disclosed
US-20230270719-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2023-08-31 US disclosed
EP-3922634-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF Gilead Sciences, Inc. (US) 2021-12-15 EP disclosed
US-20210251957-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2021-08-19 US disclosed
US-10874640-B2 Substituted pyrrolizine compounds and uses thereof GILEAD SCIENCES, INC. (US) 2020-12-29 US disclosed
US-20200061024-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2020-02-27 US disclosed
US-10328053-B2 Substituted pyrrolizine compounds and uses thereof GILEAD SCIENCES, INC. (US) 2019-06-25 US disclosed
US-20180161307-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2018-06-14 US disclosed
US-20180161307-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2018-06-14 US disclosed
WO-2018039531-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2018-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200061024-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF HMBS, DHFR, HCCS CTSB 2201/4885CTSS 3150/4885CTSL 1324/4885
US-12161625-B2 Substituted pyrrolizine compounds and uses thereof HMBS, DHFR, HCCS CTSB 2201/4885CTSS 3150/4885CTSL 1324/4885
US-10328053-B2 Substituted pyrrolizine compounds and uses thereof HMBS, DHFR, HCCS CTSB 2201/4885CTSS 3150/4885CTSL 1324/4885
US-20230270719-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF HMBS, DHFR, HCCS CTSB 2201/4885CTSS 3150/4885CTSL 1324/4885
US-10874640-B2 Substituted pyrrolizine compounds and uses thereof HMBS, DHFR, HCCS CTSB 2201/4885CTSS 3150/4885CTSL 1324/4885
US-20180161307-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF HMBS, DHFR, HCCS CTSB 2201/4885CTSS 3150/4885CTSL 1324/4885
US-20210251957-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF HMBS, DHFR, HCCS CTSB 2201/4885CTSS 3150/4885CTSL 1324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.